127 related articles for article (PubMed ID: 38006368)
21. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
22. Serum lactate dehydrogenase is a predictor of poor survival in malignant melanoma.
Gao D; Ma X
Panminerva Med; 2017 Dec; 59(4):332-337. PubMed ID: 27309261
[TBL] [Abstract][Full Text] [Related]
23. The prognostic value of preoperative serum lactate dehydrogenase levels in patients underwent curative-intent hepatectomy for colorectal liver metastases: A two-center cohort study.
Bai L; Lin ZY; Lu YX; Chen Q; Zhou H; Meng Q; Lin CP; Huang WL; Wan YL; Pan ZZ; Wang DS
Cancer Med; 2021 Nov; 10(22):8005-8019. PubMed ID: 34636145
[TBL] [Abstract][Full Text] [Related]
24. Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase.
Pelizzari G; Bertoli E; Buriolla S; Vitale MG; Basile D; Palmero L; Zara D; Iacono D; Andrea F; Pascoletti G; Bolzonello S; Garutti M; Fasola G; Puglisi F; Minisini AM
Melanoma Res; 2023 Oct; 33(5):398-405. PubMed ID: 37402350
[TBL] [Abstract][Full Text] [Related]
25. Serum S100B levels correlate with stage, N status, mitotic rate and disease outcome in melanoma patients independent to LDH.
Karonidis A; Mantzourani M; Gogas H; Tsoutsos D
J BUON; 2017; 22(5):1296-1302. PubMed ID: 29135116
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma.
Waninger JJ; Fecher LA; Lao C; Yentz S; Green MD; Demirci H
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497270
[TBL] [Abstract][Full Text] [Related]
27. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
29. Metastatic melanoma: lactate dehydrogenase levels and CT imaging findings of tumor devascularization allow accurate prediction of survival in patients treated with bevacizumab.
Gray MR; Martin del Campo S; Zhang X; Zhang H; Souza FF; Carson WE; Smith AD
Radiology; 2014 Feb; 270(2):425-34. PubMed ID: 24072776
[TBL] [Abstract][Full Text] [Related]
30. The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients.
Deckers EA; Kruijff S; Brouwers AH; van der Steen K; Hoekstra HJ; Thompson JF; Vállez García D; Wevers KP
Eur J Surg Oncol; 2020 Nov; 46(11):2147-2153. PubMed ID: 32819759
[TBL] [Abstract][Full Text] [Related]
31. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
Egberts F; Hitschler WN; Weichenthal M; Hauschild A
Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
[TBL] [Abstract][Full Text] [Related]
32. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase.
Deichmann M; Kahle B; Moser K; Wacker J; Wüst K
Br J Cancer; 2004 Aug; 91(4):699-702. PubMed ID: 15280926
[TBL] [Abstract][Full Text] [Related]
33. S-100B: a stronger prognostic biomarker than LDH in stage IIIB-C melanoma.
Wevers KP; Kruijff S; Speijers MJ; Bastiaannet E; Muller Kobold AC; Hoekstra HJ
Ann Surg Oncol; 2013 Aug; 20(8):2772-9. PubMed ID: 23512078
[TBL] [Abstract][Full Text] [Related]
34. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein.
Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE
Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of lactate dehydrogenase in patients with uveal melanoma treated with immune checkpoint inhibition.
Liang X; Zhou S; Xiao Z
Aging (Albany NY); 2023 Sep; 15(17):8770-8781. PubMed ID: 37671944
[TBL] [Abstract][Full Text] [Related]
36. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
37. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors.
Gassenmaier M; Lenders MM; Forschner A; Leiter U; Weide B; Garbe C; Eigentler TK; Wagner NB
Target Oncol; 2021 Mar; 16(2):197-205. PubMed ID: 33555543
[TBL] [Abstract][Full Text] [Related]
38. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
39. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
Agarwala SS; Keilholz U; Gilles E; Bedikian AY; Wu J; Kay R; Stein CA; Itri LM; Suciu S; Eggermont AM
Eur J Cancer; 2009 Jul; 45(10):1807-14. PubMed ID: 19419855
[TBL] [Abstract][Full Text] [Related]
40. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]